Patents by Inventor Nils U. Bang

Nils U. Bang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5270040
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce subfragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: July 1, 1992
    Date of Patent: December 14, 1993
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. R. Jaskunas, Mei-Huei T. Lai, Sheila P. Little, George L. Long, Robert F. Santerre
  • Patent number: 5244806
    Abstract: The invention discloses modified forms of the enzyme tissue plasminogen activator (t-PA) in which recombinant DNA techniques are utilized to modify the structure of the t-PA cDNA to express a modified t-PA which retains the ability to activate plasminogen yet binds less efficiently to plasmin inhibitor. The invention provides novel DNA compounds and recombinant DNA expression vectors that encode modified human t-PA wherein all or a portion of the kringle protein domains of native human t-PA are removed. Both eukaryotic and prokaryotic expression vectors containing the modified t-PA DNA have been constructed and used to transform Chinese hamster ovary cells and Escherichia coli cells.
    Type: Grant
    Filed: November 19, 1990
    Date of Patent: September 14, 1993
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Sheila P. Little, Brigitte E. Schoner, Barbara J. Weigel
  • Patent number: 5196322
    Abstract: A method for the recombinant production of zymogen forms of human protein C is described. These zymogen forms differ from native zymogen protein C in their increased sensitivity to activation by thrombin and thrombin/thrombomodulin. DNA compounds, vectors, and transformants useful in the method are also disclosed.
    Type: Grant
    Filed: October 4, 1991
    Date of Patent: March 23, 1993
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Hartmut Ehrlich, Brian W. Grinnell, S. Betty Yan
  • Patent number: 5151268
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: July 5, 1988
    Date of Patent: September 29, 1992
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. Richard Jaskunas, Mei-Huei T. Lai, Sheila P. Little, George L. Long, Robert F. Santerre
  • Patent number: 4992373
    Abstract: A method for the direct recombinant production of activated protein C is described. DNA compounds, vectors, and transformants useful in the method are also disclosed. The method involves transformation and culture of a host cell with a recombinant DNA vector that encodes a protein C molecule in which the activation peptide is replaced with a cleavage sequence for a cell associated protease.
    Type: Grant
    Filed: December 4, 1987
    Date of Patent: February 12, 1991
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Hartmut Ehrlich, Brian W. Grinnell, S. Richard Jaskunas
  • Patent number: 4775624
    Abstract: The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive expression of protein C activity when transformed into an appropriate host cell. The novel expression vectors can be used to produce protein C derivatives, such as non-carboxylated, non-glycosylated, or non-hydroxylated protein C, and to produce protein C precursors, such as nascent or zymogen protein C, and to produce sub-fragments of protein C, such as active or inactive light and heavy chain. The recombinant-produced protein C activity is useful in the treatment and prevention of a variety of vascular disorders.
    Type: Grant
    Filed: February 8, 1985
    Date of Patent: October 4, 1988
    Assignee: Eli Lilly and Company
    Inventors: Nils U. Bang, Robert J. Beckmann, S. Richard Jaskunas, Mei-Huei T. Lai, Shelia P. Little, George L. Long, Robert F. Santerre